[1]李慧玲,高红艳,杭晨,等.黑升麻制剂治疗围绝经期综合征的初步探讨[J].中国计划生育和妇产科,2019,(6):45-49.
　LI Hui-ling,GAO Hong-yan,HANG Chen,et al.Efficacy and safety of black cohosh preparation on peri-menopausal symptoms[J].Chinese Journal of Family Planning & Gynecotokology,2019,(6):45-49.
点击复制

黑升麻制剂治疗围绝经期综合征的初步探讨
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2019年6期
页码:
45-49
栏目:
论著与临床
出版日期:
2019-06-25

文章信息/Info

Title:
Efficacy and safety of black cohosh preparation on peri-menopausal symptoms
作者:
李慧玲1; 高红艳2; 杭晨3; 王清2; 李沁2; 陈继明2; 4*
1. 163000黑龙江大庆，大庆龙南康复医院妇产科；2. 213000江苏常州，苏州大学附属第三医院妇产科；3. 214000江苏无锡，无锡市妇幼保健院妇产科；4. 213000 江苏 常州，南京医科大学附属常州第二人民医院妇产科
Author(s):
LI Hui-ling1;  GAO Hong-yan2;  HANG Chen3;  WANG Qing2;  LI Qin2;  CHEN Ji-ming2; 4*
1. Department of Obstetrics and Gynecology, Daqing Longnan Rehabilitation Hospital, Daqingm Heilongjiang 163000, P.R.China；2. Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Soochow University, Changzhou Jiangsu 213000, P.R.Chi
关键词:
围绝经期综合征; Kupperman绝经指数; 黑生麻制剂; 替勃龙
Keywords:
peri-menopausal symptoms;  Kupperman menopausal index;  black cohosh preparation;  tibolone
分类号:
R 711.59
摘要:
目的探讨黑升麻制剂治疗围绝经期综合征患者的临床疗效及安全性。方法选择2010年7月至2014年3月在大庆龙南康复医院及苏州大学附属第三医院妇科门诊就诊的51例绝经早期围绝经期综合征患者为研究对象，随机分为两组，其中黑升麻组26例，给予黑升麻制剂口服，028 g，Bid，连续用药12周；替勃龙组25例，给予替勃龙片口服，25 mg，Qd，连续用药12周。以Kupperman绝经指数(Kupperman menopause index，KMI)总分以及潮热出汗评分为主要疗效指标，在治疗前、治疗第4、8、12周时进行观察比较；同时检测两组患者用药12周前后肝肾功能、血脂4项、子宫内膜厚度及血清性激素水平变化，记录两组不良反应发生情况。结果① 治疗前两组患者KMI总分、潮热出汗评分、肝肾功能、血脂4项、血清性激素水平及子宫内膜厚度比较，差异无统计学意义 (P>005)。② 两组患者治疗第4、8、12周时，KMI总分及潮热出汗评分较治疗前均明显下降(P<005)，但两组之间比较，差异无统计学意义(P>005)。③ 两组肝肾功能、血脂水平治疗前后比较，差异无统计学意义 (P>005)。④ 两组子宫内膜厚度治疗前后比较，差异无统计学意义(P>005)。⑤ 性激素变化：两组治疗前血清雌二醇(estradiol，E2)及卵泡刺激素(follicle stimulating hormone，FSH)比较，差异无统计学意义 (P>005)；黑升麻组E2及FSH治疗前后比较，差异无统计学意义(P>005)；替勃龙组治疗后E2水平高于治疗前和黑生麻组，FSH水平低于治疗前，也低于黑生麻组(P<005)。⑥ 不良反应：黑升麻组阴道出血、乳房胀痛等发生率明显低于替勃龙组(P<005)。结论黑升麻制剂治疗绝经早期妇女围绝经期综合征的效果与替勃龙相似，短期内使用对患者肝肾功能、血脂、血清性激素水平、子宫内膜厚度无明显影响；黑升麻制剂导致的阴道出血、乳房胀痛等不良事件的发生率更低。
Abstract:
ObjectiveTo investigate the clinical efficacy and safety of black cohosh preparation on peri-menopausal symptoms. Methods51 early postmenopausal women with peri-menopausal symptoms in Daqing Longnan Rehabilitation Hospital and The Third Affiliated Hospital of Soochow University from July 2010 to March 2014 were enrolled. They were divided into 2 groups randomly. The therapeutic strategy in black cohosh group (26 cases) was to take black cohosh 028 g，bid for 12 weeks, while tibolone 25 mg qd for 12 weeks in the tibolone group（25 cases）. Kupperman menopause index (KMI) total score and hot flash/sweating scores were the main curative indicators, and were compared before treatment and at 4, 8, and 12 weeks of treatment. At the same time, the changes of liver and kidney function, blood lipids, endometrial thickness and serum sex hormone levels were measured before and 12 weeks after treatment. The incidence of adverse reactions in the two groups was recorded. Results① There were no significant differences in KMI score, hot flash/sweating scores, liver and kidney function, blood lipids, serum sex hormone levels and endometrial thickness between the two groups before treatment (P>005); ② At the 4th, 8th, and 12th week of treatment, the scores of KMI and hot flash/sweating scores were significantly lower than those before treatment (P<005), but there was no significant difference between the two groups (P>005).③ There were no significant differences in liver and kidney function and blood lipid levels between the two groups before and after treatment (P>005). ④ There was no significant difference in the endometrial thickness between the two groups before and after treatment (P>005). ⑤ The post-therapeutic serum FSH and E2 level had no significant change in comparison of the initial level in black cohosh group (P>005), while in tibolone group , the level of E2 was higher than that pre- therapeutic and black cohosh group, and the FSH level was lower than that before treatment and also lower than that in the black cohosh group (P<005).⑥ The incidence of vaginal bleeding, breast distending pain in black cohosh group is remarkably lower than tibolone group (P<005). ConclusionCompared with tibolone, black cohosh had similar clinical efficacy for peri-menopausal symptoms in early postmenopausal women, and under short-term administration it had no obvious influence on liver and renal functions, blood lipid profile, serum sex hormone levels, and endometrial thickness，and had lower incidence of the adverse events such as vaginal bleeding and breast distending pain.

参考文献/References:

［1］CHEN Jiming, GAO Hongyan, LI Qin, et al. Efficacy and safety of remifemin on peri-menopausal symptoms induced by post-operative GnRH-a therapy for endometriosis: a randomized study versus tibolone ［J］. Med Sci Monit, 2014, 20(20): 1950-1957. ［2］LihongGao, Xiaojie Wu, Xia Liu, et al. Awareness of hormone replacement therapy in medical care personnel in Jiaxing, China：A questionnaire survey ［J］. Gynecol Endocrinol, 2017，34（4）: 1-4. ［3］陈继明，吴洁，浦丹华，等．子宫内膜异位症术后 GnRH-a治疗与黑升麻制剂的使用 ［J］．中国妇幼健康研究，2014，25（2）：344-347． ［4］田秦杰，徐苓，沈铿，等．黑升麻制剂治疗妇科恶性肿瘤术后绝经相关症状的初步研究 ［J］．生殖医学杂志，2011，20（3）：167-173． ［5］CHEN Ji-ming, GAO Hong-yan, YI Ding, et al. Efficacy and safety investigation of Kuntai capsule for the add-back therapy of GnRH-a administration:A randomized,double-blind,blank-and tibolone-controlled study ［J］. Chin Med J, 2015, 128(4): 427-432. ［6］陈继明，高红艳，李沁．坤泰胶囊治疗围绝经期综合征患者30例临床观察 ［J］．中医杂志，2015，56（3）：231-234． ［7］陈继明，高红艳，丁屹，等．坤泰胶囊在围绝经期综合征中的应用 ［J］．中成药，2015，37（11）：2478-2481． ［8］安泳潼，柯樱，赵亚红．黑升麻提取物治疗更年期综合征的临床应用及市场情况 ［J］．上海医药，2017，38（17）：75-78． ［9］Viereck V, Emons G, Wuttke W. Black cohosh: just another phytoestrogen? ［J］. Trends in Endocrinology and Metabolism, 2005, 16(5): 214-221. ［10］Powell SL, Gdecke T, Nikolic D, et al. In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent ［J］. J Agric Food Chem, 2008, 56(24): 11718-11726. ［11］金华，张秋霞．黑升麻肝毒性报告引起各国药政部门的关注 ［J］．国外医药:植物药分册，2006，21（6）：249-250． ［12］刘兆平，杨陟华，朱茂祥，等．黑升麻的雌激素活性及其对人类乳腺癌MCF-7细胞 雌激素受体水平的影响 ［J］．卫生研究，2001，30（2）：77-80． ［13］李轶琳，崔满华，高双．黑升麻类药物莉芙敏治疗更年期症状临床疗效观察 ［J］．现代妇产科进展，2011，20（6）：462-465． ［14］胡光民，刘艳，王海颖，等．黑升麻对去卵巢大鼠子宫内膜及血清雌激素水平的影响 ［J］．中国中医药杂志，2008，6（5）：26-28． ［15］白文佩，王淑玉，刘建立，等．莉芙敏片与替勃龙改善围绝经期症状的效果和安全性比较 ［J］．中华妇产科杂志，2009，44（8）：597-600． ［16］BAI Wenpei, Henneicke-Von Zepelin HH, WANG Shuyu, et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone ［J］. Maturitas, 2007, 58(1): 31-41. ［17］杨敬红，张潇月，郑瑜．不同治疗方法在绝经早期妇女中的应用效果对比 ［J］．重庆医学，2017，46（34）：4834-4836． ［18］Rebbeck TR, Troxel AB, Norman S, et al. A retrospective case-control study of the use of hormone-related supplements and association with breast cancer ［J］. Int J Cancer, 2007, 120(7): 1523-1528. ［19］中华医学会妇产科学分会绝经学组. 莉芙敏临床应用指导建议 ［J］. 中国实用妇科与产科杂志, 2012, 28(7): 556-557.

相似文献/References:

[1]丁岩,刘新莲.卵巢早衰的临床诊治[J].中国计划生育和妇产科,2014,(02):0.
　DING Yan,LIU Xin-lian,[J].Chinese Journal of Family Planning & Gynecotokology,2014,(6):0.
[2]吕俊丽,郭钰珍.酒泉市医务人员激素补充治疗的认知现状调查[J].中国计划生育和妇产科,2014,(02):0.
　LV Jun-li,GUO Yu-zhen,[J].Chinese Journal of Family Planning & Gynecotokology,2014,(6):0.
[3]朱晔,谈诚,王彦洁,等.北京市社区妇女更年期症状及相关影响因素调查[J].中国计划生育和妇产科,2014,(09):0.
　ZHU Ye,TAN Cheng,WANG Yan-jie,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2014,(6):0.

更新日期/Last Update: 2019-06-25